Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-018-0714-5
Abstract: Background and ObjectiveTolvaptan, an oral vasopressin V2 receptor antagonist, has been widely used for the treatment of patients with cirrhosis and ascites. However, its efficacy in patients with renal dysfunction remains unknown. The objective of… read more here.
Keywords: treatment; group; ckd ckd; ckd group ... See more keywords